Meril Diagnostics Private Limited

Meril Diagnostics Private Limited, incorporated on April 18, 2011, is a private unlisted company based in Vapi, Gujarat, India. The company specializes in the manufacture of medical devices and diagnostic products, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U33110GJ2011PTC064994.

The authorized share capital of Meril Diagnostics is ₹293.00 crore, with a paid-up capital of ₹292.47 crore. The company is privately held, with promoter holdings accounting for 92.83% as of the latest available data. The registered office is located at No. 135/139, Bilakhia House, Muktanand Marg, Chala, Vapi, Gujarat, India, 396191.

Meril Diagnostics operates a state-of-the-art manufacturing facility in Vapi, Gujarat, India. The facility spans 300,000 square feet and is equipped with advanced technology to produce a wide range of diagnostic products. This includes analyzers and reagents for clinical biochemistry, hematology, immunology, and other diagnostic applications.

The company's leadership includes Directors Pramodkumar Minocha and Rajnikant Gandalal Vyas, both appointed on April 18, 2011. Additionally, Vishakha Kiran Sonaje serves as the Company Secretary, appointed on September 9, 2024.

Meril Diagnostics has made significant strides in obtaining regulatory approvals for its products in various international markets. In March 2026, the World Health Organization (WHO) issued a Medical Product Alert concerning certain in vitro diagnostic medical devices manufactured by Meril Diagnostics Pvt. Ltd. This alert was directed to national regulatory authorities and users, including control programs and procurement agencies. (who.int)

Meril Diagnostics has been actively expanding its presence in emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's commitment to quality and innovation has facilitated its entry into these regions, enabling access to a broader customer base. However, as of March 2026, specific details regarding WHO prequalification for Meril Diagnostics' products are not publicly available. (who.int)

Meril Diagnostics has adopted a strategic approach to geographic diversification, focusing on both developed and emerging markets. This strategy aims to mitigate concentration risk and leverage growth opportunities across different regions. The company's expansion into various international markets reflects its commitment to becoming a global player in the diagnostics industry.

As of March 2026, specific details regarding Meril Diagnostics' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company has not publicly disclosed information regarding its interactions with the U.S. Food and Drug Administration (FDA).

In December 2025, the World Health Organization (WHO) issued a Notice of Concern (NOC) for Meril Diagnostics Pvt. Ltd., indicating potential issues with certain in vitro diagnostic medical devices manufactured by the company. This notice was published on December 19, 2025, and is accessible through the WHO Prequalification Unit's website. (extranet.who.int)

Meril Diagnostics holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company complies with the regulatory requirements set forth by the CDSCO and state drug controllers, ensuring the safety and efficacy of its products. Additionally, Meril Diagnostics has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its international trade activities.

In March 2026, the World Health Organization (WHO) issued a Medical Product Alert concerning certain in vitro diagnostic medical devices manufactured by Meril Diagnostics Pvt. Ltd. This alert was directed to national regulatory authorities and users, including control programs and procurement agencies. (who.int)

Meril Diagnostics operates in a competitive landscape with several key players in the diagnostics industry. The company's focus on innovation and quality has enabled it to establish a strong presence in both domestic and international markets. While specific market share data is not publicly available, Meril Diagnostics' strategic initiatives and product offerings position it as a significant competitor in the diagnostics sector.

Meril Diagnostics distinguishes itself through its commitment to innovation, quality, and customer-centric approach. The company's state-of-the-art manufacturing facilities and comprehensive product portfolio, including analyzers and reagents for various diagnostic applications, underscore its dedication to meeting the evolving needs of the healthcare industry.

Meril Diagnostics is strategically positioned to capitalize on the growing demand for diagnostic products globally. The company's focus on research and development, coupled with its expansion into emerging markets, reflects a strategic direction aimed at becoming a leading player in the diagnostics industry. Future outlooks suggest continued growth and innovation, with an emphasis on enhancing product offerings and market reach.

Meril Diagnostics has demonstrated a strong track record in manufacturing and exporting diagnostic products. The company's export volume and consistency indicate reliability in meeting international demand. However, the recent WHO Medical Product Alert in March 2026 highlights the importance of ongoing vigilance and quality assurance in maintaining supplier reliability. (who.int)

Importers should verify the following certifications when considering Meril Diagnostics as a supplier:

• FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulations.

• WHO Prequalification: Check for WHO prequalification status, which indicates adherence to international quality standards.

• EU GMP Certification: Verify the company's compliance with European Union Good Manufacturing Practice (GMP) standards.

• ISO Certifications: Ensure the company holds relevant ISO certifications, such as ISO 13485 for medical devices, to confirm quality management system compliance.

When conducting due diligence on Meril Diagnostics, consider the following steps:

• Regulatory Compliance: Verify the company's compliance with relevant regulatory bodies, including the FDA, WHO, and EU authorities.

• Quality Assurance: Review the company's quality management systems and certifications to ensure product quality.

• Financial Stability: Assess the company's financial health through audited financial statements and credit reports.

• Supply Chain Reliability: Evaluate the company's supply chain processes and history of meeting delivery commitments.

• Reputation: Research the company's reputation in the industry, including any past regulatory actions or product recalls.

Be cautious of any discrepancies in product information, regulatory approvals, or financial reporting, as these may indicate potential risks.